|
Oct 14
|
Ipsen receives its second Shingo Prize for operational excellence
|
|
Oct 9
|
Ipsen SA (IPSEF) (H1 2024) Earnings Call Highlights: Strong Sales Growth Amidst Challenges
|
|
Oct 9
|
Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
|
|
Jul 26
|
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
|
|
Jul 25
|
Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy
|
|
Jul 25
|
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
|
|
Jul 25
|
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
|
|
Jul 23
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024
|
|
Jun 18
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024
|
|
Jun 11
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024
|
|
Jun 11
|
Ipsen drug for rare liver disease approved by FDA
|
|
Jun 10
|
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
|
|
Dec 7
|
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
|
|
Dec 7
|
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
|
|
Nov 14
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2023
|
|
Nov 7
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2023
|
|
Nov 6
|
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
|
|
Sep 26
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2023
|
|
Aug 8
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2023
|